R&D Bioanalytical labs need to reimagine data to streamline thei... The fundamental questions in the trial phases of drug development are “Does it work?”, “Is it safe?”, and “What else do we need to know?”
R&D Big pharma places big bets on antibody-drug conjugates Antibody-drug conjugates have emerged as one of the most popular treatment modalities for investment in recent years.
R&D Universities and pharma companies need each other to create ... Academics and pharma executives seemingly live in very different worlds.
R&D Threats impacting the pharmaceutical industry in 2024 As we approach 2024, what will the next 12 months have in store for pharma?
R&D Is the future of pharmaceutical drugs in the delivery? Pharmaceutical drugs have seen a seismic shift over the past ten years, moving away from chemically synthesised drugs to focus more on a new class of biological drugs (biologics).<
News MSD gets first FDA okay for oral PCSK9 cholesterol drug MSD has won the race to bring an oral PCSK9 inhibitor through to regulatory approval for LDL cholesterol-lowering in the US.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.